Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease

Zheng, Xiaoyao; Shao, Xia; Zhang, Chi; Tan, Yuanzhen; Li, Qingfeng; Xu, Wenrong; Zhang, Qizhi; Xu, Sihua; Jiang, Xinguo

doi:10.1007/s11095-015-1744-9

Cited by 149 publications

(63 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[84][85][86][87]91 Once encapsulated into liposomes, the H102 peptide, a β-sheet breaker, was able to block the early steps of aggregation and misfolding of the soluble Aβ, improving the spatial memory impairment of AD in rats. 112 α-Mangostin is a polyphenolic xanthone that exhibits pharmacological effects, such as anti-inflammation, antioxidant, and antitumor effects. When administered intravenously, α-mangostin liposomes have been shown to protect and improve the neurons against Aβ-oligomer toxicity in rats.…”

Section: Data Extractionmentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

349

238

View full text Add to dashboard Cite

This review summarizes articles that have been reported in literature on liposome-based strategies for effective drug delivery across the blood–brain barrier. Due to their unique physicochemical characteristics, liposomes have been widely investigated for their application in drug delivery and in vivo bioimaging for the treatment and/or diagnosis of neurological diseases, such as Alzheimer’s, Parkinson’s, stroke, and glioma. Several strategies have been used to deliver drug and/or imaging agents to the brain. Covalent ligation of such macromolecules as peptides, antibodies, and RNA aptamers is an effective method for receptor-targeting liposomes, which allows their blood–brain barrier penetration and/or the delivery of their therapeutic molecule specifically to the disease site. Additionally, methods have been employed for the development of liposomes that can respond to external stimuli. It can be concluded that the development of liposomes for brain delivery is still in its infancy, although these systems have the potential to revolutionize the ways in which medicine is administered.

show abstract

Section: Data Extractionmentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

349

238

View full text Add to dashboard Cite

show abstract

“…This route of administration is of interest since the drug/s can be directly delivered to the brain aptly crossing the blood-brain barrier (BBB) (Kozlovskaya et al, 2014). Utilizing this mode of carrier mechanism, various studies have used administration of intranasal liposomes in many diseases, such as Alzheimer (Corace et al, 2014; Zheng et al, 2015), Parkinson (Migliore et al, 2014) and tuberculosis (Leemans et al, 2001). Also, intranasal liposomes have also been used in the preparation of vaccines against bacterial and fungal infectious diseases such as pneumonia, influenza, and tuberculosis (Khatri et al, 2008; Romero and Morilla, 2011; Tada et al, 2015; Tiwari et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells

Vaz

Sharma

Zheng

et al. 2016

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Background Liposomes are concentric lipid vesicles that allow a sustained release of entrapped substances. GABA (γ-aminobutyric acid) is the most prevalent inhibitory neurotransmitter in the central nervous system. New method Using GABA-containing liposomes (GL) prepared by the freeze-thawing method, we determined the effect of sustained release of GABA on expression of neuronal nitric oxide synthase (nNOS) and GABAA receptor (GABAAR) in an in vitro neuronal model. Results Neuronal cell line NG108-15 treated with different doses of GL during 24 h showed an increase in expression of GABAAR (54 and 50% with 10 and 20 ng doses, respectively) and nNOS (138, 157 and 165% with 20, 50 and 100 ng doses, respectively) compared with cells treated with empty liposomes (EL). Additionally, cells treated with 50 ng of GL showed an increase in GABAAR (23%) after 1h followed by an increase in nNOS (55, 46 and 55%) at 8, 12 and 24h time points, respectively. Immunofluorescence experiments confirmed an increase in nNOS (134%) and basal intracellular levels of nitric oxide (84%) after GL treatment. Further, treatment of cells with GL showed a decrease in expression of protein inhibitor of nNOS (PIN) (26, 66 and 57% with 20, 50 and 100 ng doses respectively) compared with control. Comparison with existing methods This is first demonstration for the development of GL that allows sustained slow release of this neurotransmitter. Conclusion These results suggest that a slow release of GABA can change the expression of nNOS possibly via alteration in PIN levels in neuronal cells.

show abstract

“…After intracerebro-ventricular injection, it could improve the spatial memory impairment of Aβ precursor protein (APP) transgenic mice and reduce the quantity of senile plaques and the level of APP and Aβ, as well as enhance the activity of choline acetyltransferase (ChAT) and decrease the activity of acetylcholinesterase (AchE). This indicates that H102 maybea promising drug for AD treatment [4].The second one, a result shows that bi-functionalizd mApoE-PA-LIP significantly destabilize preformed Aβ42 aggregates, mApoE-PA-LIP did not affect the cell viability, BBB monolayer integrity, NO production and did not induce ER stress. residues on Aβ aggregates.…”

Section: Liposomes In the Treatment Of Alzheimer's Diseasementioning

confidence: 90%

Targeted Therapies for Alzheimer's Disease: An Overview

Sun¹,

Xiu²,

Ying³

2017

Proceedings of the 2nd International Conference on Biomedical and Biological Engineering 2017 (BBE 2017)

View full text Add to dashboard Cite

Dementia is the most common onset of Alzheimer's disease (AD). The main neuropathological characteristics of AD are extracellular amyloid plaques and intracellular accumulation of hyperphosphorylated Tau protein. Because of the complexity of the pathogenesis, the most treatment options are not effective at present. Conventional treatmentstrategies, acety-lcholinesterase inhibitors and N-methyl-d-aspartate receptor antagonists, are only able to alleviate the symptoms of AD. The research on AD therapy has had limited success .Consequently, targeted therapy will become potential ways to treat Alzheimer's disease in the future. This paper makes a brief review on this aspect.

show abstract

Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease

Abstract: The H102-loaded liposome prepared in this study for nasal administration is stable, effective and safe, which has great potential for AD treatment.

Cited by 149 publications

References 40 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells

Targeted Therapies for Alzheimer's Disease: An Overview

Contact Info

Product

Resources

About

Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease

Abstract: The H102-loaded liposome prepared in this study for nasal administration is stable, effective and safe, which has great potential for AD treatment.

Cited by 149 publications

References 40 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells

Targeted Therapies for Alzheimer's Disease: An Overview

Contact Info

Product

Resources

About

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier